Publications

Detailed Information

Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cells

DC Field Value Language
dc.contributor.authorLee, Chang Seok-
dc.contributor.authorShin, Yong Jae-
dc.contributor.authorWon, Cheolhee-
dc.contributor.authorLee, Yun-Song-
dc.contributor.authorYe, Sang-Kyu-
dc.contributor.authorChung, Myung-Hee-
dc.contributor.authorPark, Chung-Gyu-
dc.date.accessioned2012-07-02T08:34:27Z-
dc.date.available2012-07-02T08:34:27Z-
dc.date.issued2009-08-
dc.identifier.citationBIOCELL; Vol.33 2; 107-114ko_KR
dc.identifier.issn0327-9545-
dc.identifier.urihttps://hdl.handle.net/10371/78128-
dc.description.abstractCyclooxygenase-2 (COX-2) is a key inflammatory response molecule,,in(] associated with Many immune functions of monocytes/macrophages. Particularly, interferon gamma (IFN gamma)-induced COX-2 expression appears in inflammatory conditions such as viral infection and autoimmune diseases. Recently statins have been reported to show variable effects oil COX-2 expression, and oil their cell and species type dependences. Based on the above description, we compared the effect of simvastatin on IFN gamma-induced COX-2 expression in human monocytes versus murine macrophages. In a result, we found that simvastatin suppresses IFN gamma-induced COX-2 expression in human THP-1 monocytes, but rather, potentiates IFN gamma-induced COX-2 expression in murine RAW264.7 macrophages. However, signal transducer and activator of transcription 1/3 (STAT1/3), known as a transcription factor oil COX-2 expression, is inactivated by simvastatin in both cells. Our findings showed that simvastatin is likely to Suppress IFN gamma-induced COX-2 expression by inhibiting STAT1/3 activation in human THP-1 cells, but not in murine RAW264.7 cells. Thus, we concluded that IFN gamma-induced COX-2 expression is differently regulated by simvastatin depending oil species specific mechanism.ko_KR
dc.language.isoenko_KR
dc.publisherUniversidad Nacional de Cuyoko_KR
dc.subjectmonocyteko_KR
dc.subjectSOCS 1/3ko_KR
dc.subjectmacrophageko_KR
dc.subjectINF gammako_KR
dc.subjectSTAT 1/3ko_KR
dc.titleSimvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264.7 cellsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이창석-
dc.contributor.AlternativeAuthor신용재-
dc.contributor.AlternativeAuthor원철희-
dc.contributor.AlternativeAuthor이윤송-
dc.contributor.AlternativeAuthor박정규-
dc.contributor.AlternativeAuthor예상규-
dc.contributor.AlternativeAuthor정명희-
dc.citation.journaltitleBIOCELL-
dc.description.citedreferenceLee SJ, 2007, J LEUKOCYTE BIOL, V82, P436, DOI 10.1189/jlb.1206739-
dc.description.citedreferenceChen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023-
dc.description.citedreferenceKim YS, 2007, J CARDIOVASC PHARM, V49, P376-
dc.description.citedreferenceHabib A, 2007, FASEB J, V21, P1665, DOI 10.1096/fj.06-6766com-
dc.description.citedreferenceYano M, 2007, CIRC RES, V100, P1442, DOI 10.1161/01.RES.0000268411.49545.9c-
dc.description.citedreferenceChello M, 2007, ANN THORAC SURG, V83, P1374, DOI 10.1016/j.athoracsur.2006.10.065-
dc.description.citedreferenceTunon J, 2007, EXPERT OPIN THER TAR, V11, P273, DOI 10.1517/14728222.11.3.273-
dc.description.citedreferenceGreenwood J, 2007, TRENDS IMMUNOL, V28, P88-
dc.description.citedreferenceGhittoni R, 2006, EUR J IMMUNOL, V36, P2885, DOI 10.1002/eji.200636567-
dc.description.citedreferenceKuipers HF, 2005, HUM IMMUNOL, V66, P653, DOI 10.1016/j.humimm.2005.04.004-
dc.description.citedreferenceChen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016/j.yexcr.2004.05.039-
dc.description.citedreferenceQing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200-
dc.description.citedreferenceKOBASHIGAWA JA, 2004, SEMIN VASC MED, V4, P401-
dc.description.citedreferenceMiller LJ, 2004, ANN PHARMACOTHER, V38, P91, DOI 10.1345/aph.1D104-
dc.description.citedreferenceLIAO JK, 2004, INT J CLIN PRACT, V143, P41-
dc.description.citedreferenceHuang KC, 2003, FEBS LETT, V555, P385, DOI 10.1016/S0014-5793(03)01297-3-
dc.description.citedreferenceMonick MM, 2003, J IMMUNOL, V171, P2625-
dc.description.citedreferenceHuang KC, 2003, J BIOMED SCI, V10, P396, DOI 10.1159/000071159-
dc.description.citedreferenceXuan YT, 2003, J MOL CELL CARDIOL, V35, P525, DOI 10.1016/S0022-2828(03)00076-2-
dc.description.citedreferenceChung HK, 2002, EXP MOL MED, V34, P451-
dc.description.citedreferenceDegraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074/jbc.M104197200-
dc.description.citedreferenceSadeghi MM, 2001, TRANSPLANTATION, V71, P1262-
dc.description.citedreferenceKiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105-
dc.description.citedreferenceGrip O, 2000, EUR J PHARMACOL, V410, P83-
dc.description.citedreferenceChen H, 2000, HYPERTENSION, V36, P923-
dc.description.citedreferenceYasukawa H, 2000, ANNU REV IMMUNOL, V18, P143-
dc.description.citedreferenceOrtego M, 1999, ATHEROSCLEROSIS, V147, P253-
dc.description.citedreferenceInoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143-
dc.description.citedreferenceDecker T, 1997, J INTERF CYTOK RES, V17, P121-
dc.description.tc2-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share